



What is claimed is:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,



wherein,

ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, C₅₋₇ cycloalkenyl and C₅₋₇ cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, C₅₋₇ cycloalkenyl and C₅₋₇ cycloalkyl are optionally substituted with R₆;



and the structural unit is not selected from:

R₁ is selected from H, halogen, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyloxy, and C₃₋₆ cycloalkyloxy, wherein the C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₂₋₆ alkenyloxy and C₃₋₆ cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups;

R₂ is selected from H, halogen, CN, OH, NO₂, NH₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₄ cycloalkyl, C₃₋₆ cycloalkenyl, C₄₋₆ cycloalkynyl, phenyl, and 3- to 14-membered heterocyclic groups, wherein said NH₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₄ cycloalkyl, C₃₋₆ cycloalkenyl, C₄₋₆ cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups;

R₃ is selected from H, halogen, C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, C₃₋₆ cycloalkyloxy, -OC(=O)NH₂, -OC(=O)NHR, -OC(=O)NRR, -NRC(=O)OR, -NHC(=O)OR, -NHC(=O)OH, -O(CH₂)_nNR_aR_b, C₁₋₆ alkyl, C₃₋₆ cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2, or 3 N or O atoms, wherein said C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups;

n is selected from 0, 1, 2, 3 or 4;

R_a and R_b are each independently selected from H, C₁₋₅ alkyl and C₁₋₅ heteroalkyl, and said C₁₋₅ alkyl and C₁₋₅ heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R_a and R_b are bonded together to form a 5- to 6-membered heterocyclic ring;

R₄ and R₅ are each independently selected from H, halogen, CN, NH₂, C₁₋₄ alkyl, C₁₋₄ heteroalkyl, C₃₋₆ cycloalkyl, phenyl, and 5- to 6-membered heterocyclic group, wherein said NH₂, C₁₋₄ alkyl, C₁₋₄ heteroalkyl, C₃₋₆ cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups;

or alternatively, R₄ and R₅ are bonded together to form a 5- to 6-membered ring containing 1, 2, or 3 atoms independently selected from N, S or O, wherein the 5- to 6-

membered ring is optionally substituted with 1, 2 or 3 R groups;

each R₆ is independently selected from H, halogen, CN, OH, NH₂, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, =O and =S;

R₇ and R₈ are each independently selected from H or C₁₋₆ alkyl;

or alternatively R₇ and R₈ are bonded together to form a 5- to 6-membered heterocyclic ring, and the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups;


R is selected from halogen, CN, OH, NH₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkenyl, C₄₋₆ cycloalkynyl, C₁₋₆ heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkenyl, C₄₋₆ cycloalkynyl, C₁₋₆ heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups;

R' is selected from H, F, Cl, Br, I, CN, OH, NH₂, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, CH₃O, CF₃, CHF₂ and CH₂F;

"hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C₁₋₄ heteroalkyl, C₁₋₅ heteroalkyl, C₁₋₆ heteroalkyl, 3- to 6-membered heterocycloalkyl, and 5- to 6-membered heteroaryl is independently selected from -C(=O)N(R)-, -N(R)-, -C(=NR)-, -(R)C=N-, -S(=O)₂N(R)-, -S(=O)N(R)-, N-, -NH-, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)₂- and -N(R)C(=O)N(R)-;


in any one of the cases as described above, the number of the heteroatom or heteroatomic group is each independently selected from 1, 2, or 3.

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R is selected from F, Cl, Br, I, CN, OH, NH₂, CH₃, CH₃CH₂, CH₃CH₂CH₂,




3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R₁ is selected from H, halogen, C₁₋₃ alkyl, C₁₋₃ heteroalkyl, C₂₋₅ alkenyloxy, and C₄₋₆ cycloalkyloxy, wherein said C₁₋₃ alkyl, C₁₋₃ heteroalkyl, C₂₋₅ alkenyloxy and C₄₋₆ cycloalkyloxy are optionally substituted with 1, 2, or 3 R groups.

4. The compound or the pharmaceutically acceptable salt thereof according to claim 3, wherein R₁ is selected from H, F, Cl, Br, I, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH,




5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R₂ is selected from H, halogen, CN, OH, NO₂, NH₂, C₃₋₁₂ cycloalkyl, and 3- to 12-membered heterocycloalkyl, wherein said NH₂, C₃₋₁₂ cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups.


6. The compound or the pharmaceutically acceptable salt thereof according to claim 5,




wherein R₂ is selected from H, halogen, CN, OH, NH₂, NO₂, -NHR, -N(R)₂, $\begin{smallmatrix} \text{N} \\ | \\ \text{H} \end{smallmatrix}$,



7. The compound or the pharmaceutically acceptable salt thereof according to claim 6,



wherein R₂ is selected from H, F, Cl, Br, CN, OH, NH₂, NO₂, $\begin{smallmatrix} \text{N} \\ | \\ \text{H} \end{smallmatrix}$, $\begin{smallmatrix} \text{I} \\ | \\ \text{H} \end{smallmatrix}$, $\begin{smallmatrix} \text{N} \\ | \\ \text{H} \end{smallmatrix}$,




8. The compound or thea pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R₆ is selected from H, F, Cl, Br, CN, OH, NH₂, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, CH₃O, =S and =O.

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl,


cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl, and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl, and pyrrolyl are optionally substituted with R₆.

10. The compound or the pharmaceutically acceptable salt thereof according to claim




11. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R_a and R_b are each independently selected from H, CH₃, CH₃CH₂, and -S(=O)₂CH₃, wherein said CH₃, CH₃CH₂ and -S(=O)₂CH₃ are optionally substituted with 1, 2 or 3 R groups.


12. The compound or the pharmaceutically acceptable salt thereof according to claim




13. The compound or the pharmaceutically acceptable salt thereof according to claim







14. The compound or the pharmaceutically acceptable salt thereof according to claim 1




15. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R₅ is selected from H, F, Cl, Br, I, CN, CH₃, CH₃CH₂, CH₃CH₂CH₂,





wherein said CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH, , , , , ,  and  are optionally substituted with 1, 2 or 3 R groups.

16. The compound or the pharmaceutically acceptable salt thereof according to claim 15, wherein R₅ is selected from H, Cl, Br, CN, CH₃, CH₃CH₂, CH₃CH₂CH₂, (CH₃)₂CH,




17. The compound or the pharmaceutically acceptable salt thereof according to claim 1




18. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R₇ and R₈ are each independently selected from H or CH₃.


19. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 18, which is selected from




(II)




(III)




(IV)




(V)




(VI)



(VII)



(VIII)



(IX)

wherein,

R₁ is as defined in any one of claims 1-4,

R₂ is as defined in any one of claims 1-2 or 5-7,

R₃ is as defined in any one of claims 1-2 or 13-14,


R₄ is as defined in claims 1-2 or 17,

R₅ is as defined in any one of claims 1-2 or 15-17,


R₆ is as defined in any one of claims 1-2 or 8,

R₇ and R₈ are as defined in any one of claims 1-2 or 18.


20. The compound or the pharmaceutically acceptable salt thereof according to claim 19, which is selected from



(V-1)




(V-2)





(V-3)


wherein R₁, R₃, R₄, R₅, R₇, R₈, R and R' are as defined in claim 19.


21. A compound or a pharmaceutically acceptable salt thereof, which is selected from

















22. A pharmaceutical composition comprising a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, and a pharmaceutically acceptable carrier.

23. Use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, or the pharmaceutical composition according to claim 22 in preparing a medicament for treating lung cancer.

24. The use according to claim 23, wherein the cancer is lung cancer.

2524. Use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21 or the pharmaceutical composition according to claim 22 in combination with an EGFR monoclonal antibody in preparing a medicament for treating lung cancer.

26. A method for treating cancer, comprising administering to a subject a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21 or the pharmaceutical composition according to claim 22.

27. A method for treating cancer, comprising administering to a subject a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21 or the pharmaceutical composition according to claim 22, and an EGFR monoclonal antibody.

~~28. The method according to claim 27, wherein the EGFR monoclonal antibody is cetuximab.~~

~~29. A method for treating cancer, comprising administering to a subject a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21 or the pharmaceutical composition according to claim 22, and a MEK inhibitor.~~